BriaCell and BriaPro to Present Preclinical Findings at SITC 2026
BriaCell and its majority-owned subsidiary BriaPro plan to present preclinical anti-cancer activity and immunotherapy findings at SITC 2026.
BriaCell and its majority-owned subsidiary BriaPro plan to present preclinical anti-cancer activity and immunotherapy findings at SITC 2026.